Cargando…
Non-Alcoholic Fatty Liver Disease: Translating Disease Mechanisms into Therapeutics Using Animal Models
Nonalcoholic fatty liver disease (NAFLD) is a range of pathologies arising from fat accumulation in the liver in the absence of excess alcohol use or other causes of liver disease. Its complications include cirrhosis and liver failure, hepatocellular carcinoma, and eventual death. NAFLD is the most...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10298283/ https://www.ncbi.nlm.nih.gov/pubmed/37373143 http://dx.doi.org/10.3390/ijms24129996 |
_version_ | 1785064076962955264 |
---|---|
author | Basha, Amina May, Sarah C. Anderson, Ryan M. Samala, Niharika Mirmira, Raghavendra G. |
author_facet | Basha, Amina May, Sarah C. Anderson, Ryan M. Samala, Niharika Mirmira, Raghavendra G. |
author_sort | Basha, Amina |
collection | PubMed |
description | Nonalcoholic fatty liver disease (NAFLD) is a range of pathologies arising from fat accumulation in the liver in the absence of excess alcohol use or other causes of liver disease. Its complications include cirrhosis and liver failure, hepatocellular carcinoma, and eventual death. NAFLD is the most common cause of liver disease globally and is estimated to affect nearly one-third of individuals in the United States. Despite knowledge that the incidence and prevalence of NAFLD are increasing, the pathophysiology of the disease and its progression to cirrhosis remain insufficiently understood. The molecular pathogenesis of NAFLD involves insulin resistance, inflammation, oxidative stress, and endoplasmic reticulum stress. Better insight into these molecular pathways would allow for therapies that target specific stages of NAFLD. Preclinical animal models have aided in defining these mechanisms and have served as platforms for screening and testing of potential therapeutic approaches. In this review, we will discuss the cellular and molecular mechanisms thought to contribute to NAFLD, with a focus on the role of animal models in elucidating these mechanisms and in developing therapies. |
format | Online Article Text |
id | pubmed-10298283 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-102982832023-06-28 Non-Alcoholic Fatty Liver Disease: Translating Disease Mechanisms into Therapeutics Using Animal Models Basha, Amina May, Sarah C. Anderson, Ryan M. Samala, Niharika Mirmira, Raghavendra G. Int J Mol Sci Review Nonalcoholic fatty liver disease (NAFLD) is a range of pathologies arising from fat accumulation in the liver in the absence of excess alcohol use or other causes of liver disease. Its complications include cirrhosis and liver failure, hepatocellular carcinoma, and eventual death. NAFLD is the most common cause of liver disease globally and is estimated to affect nearly one-third of individuals in the United States. Despite knowledge that the incidence and prevalence of NAFLD are increasing, the pathophysiology of the disease and its progression to cirrhosis remain insufficiently understood. The molecular pathogenesis of NAFLD involves insulin resistance, inflammation, oxidative stress, and endoplasmic reticulum stress. Better insight into these molecular pathways would allow for therapies that target specific stages of NAFLD. Preclinical animal models have aided in defining these mechanisms and have served as platforms for screening and testing of potential therapeutic approaches. In this review, we will discuss the cellular and molecular mechanisms thought to contribute to NAFLD, with a focus on the role of animal models in elucidating these mechanisms and in developing therapies. MDPI 2023-06-10 /pmc/articles/PMC10298283/ /pubmed/37373143 http://dx.doi.org/10.3390/ijms24129996 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Basha, Amina May, Sarah C. Anderson, Ryan M. Samala, Niharika Mirmira, Raghavendra G. Non-Alcoholic Fatty Liver Disease: Translating Disease Mechanisms into Therapeutics Using Animal Models |
title | Non-Alcoholic Fatty Liver Disease: Translating Disease Mechanisms into Therapeutics Using Animal Models |
title_full | Non-Alcoholic Fatty Liver Disease: Translating Disease Mechanisms into Therapeutics Using Animal Models |
title_fullStr | Non-Alcoholic Fatty Liver Disease: Translating Disease Mechanisms into Therapeutics Using Animal Models |
title_full_unstemmed | Non-Alcoholic Fatty Liver Disease: Translating Disease Mechanisms into Therapeutics Using Animal Models |
title_short | Non-Alcoholic Fatty Liver Disease: Translating Disease Mechanisms into Therapeutics Using Animal Models |
title_sort | non-alcoholic fatty liver disease: translating disease mechanisms into therapeutics using animal models |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10298283/ https://www.ncbi.nlm.nih.gov/pubmed/37373143 http://dx.doi.org/10.3390/ijms24129996 |
work_keys_str_mv | AT bashaamina nonalcoholicfattyliverdiseasetranslatingdiseasemechanismsintotherapeuticsusinganimalmodels AT maysarahc nonalcoholicfattyliverdiseasetranslatingdiseasemechanismsintotherapeuticsusinganimalmodels AT andersonryanm nonalcoholicfattyliverdiseasetranslatingdiseasemechanismsintotherapeuticsusinganimalmodels AT samalaniharika nonalcoholicfattyliverdiseasetranslatingdiseasemechanismsintotherapeuticsusinganimalmodels AT mirmiraraghavendrag nonalcoholicfattyliverdiseasetranslatingdiseasemechanismsintotherapeuticsusinganimalmodels |